Massachusetts Prostate Cancer Coalition

Plan to attend!

20TH ANNIVERSARY MASSACHUSETTS PROSTATE CANCER SYMPOSIUM
Friday, May 12, 2017
7:30 AM – 1:00 PM
Boston Marriott Copley Place
Boston, Massachusetts

Charles Austin Award for Outstanding Service in Prostate Cancer Awareness
Established in 2006 to honor Charles Austin, an outstanding member of MPCA. The award is presented to an individual who has supported the mission of MPCA and serves as a model for others.

Jack Colbert Memorial Award
Established in 2003 to honor a founding member of MPCA, the Colbert Award is presented to an individual who has made a significant impact on the field of prostate cancer and has contributed to the advancement of prostate cancer research and treatment.

Prostate Cancer State of the Art — State of the Disease
We are pleased to present the 20th anniversary prostate cancer symposium featuring keynote speakers from the last 20 years. The outstanding individuals will discuss “State of the Art — State of the Disease” in these separate panels that highlight how the diagnosis, treatment and research on prostate cancer have evolved — and what the future holds.

Don’t miss this outstanding event especially designed for men-at-risk, newly diagnosed, survivors, and their families. Primary care doctors are also encouraged to attend.

The symposium includes three panels featuring leaders in the field of prostate cancer:

- Prevention and Screening
  - Peter C. Albertsen, MD, UConn Health Center
  - J. Jacques Carrier, MD, Beth Israel Deaconess Medical Center
  - Marc B. Garnick, MD, Beth Israel Deaconess Medical Center
  - Andrew Vickers, Ph.D., Memorial Sloan Kettering Cancer Center, moderator

- Active Surveillance and Early Stage Disease
  - Clair J. Brant, MD, Brigham and Women’s Hospital/Dana-Farber Cancer Institute
  - Adam S. Kibel, MD, Brigham and Women’s Hospital
  - Eric A. Klein, MD, Cleveland Clinic
  - Laurence Knott, MD, University of Toronto, moderator
  - Clare M. Tompany, MD, Brigham and Women’s Hospital

- Metastatic Disease and Research
  - William G. Nelson, MD, Johns Hopkins University School of Medicine
  - Susan F. Slawin, MD, Memorial Sloan Kettering Cancer Center
  - Mary Ellen Taplin, MD, Dana-Farber Cancer Institute, moderator

Sponsors to Date
- Beth Israel Deaconess Medical Center
- Brigham and Women’s Hospital
- Dana-Farber Cancer Institute
- David Goodkin
- Garth and Lindsey Greimann
- Massachusetts Prostate Cancer Coalition
- Allen L. Snyder III

EDUCATIONAL GRANTS
- AdMeTech Foundation
- Cancer Research Foundation / ZERO
- Million Dollar Roundtable (MDRT) Foundation
Symposium Schedule

7:30AM Registration and Breakfast

8:00 Panel on Prevention and Screening
Prostate cancer is one of the few cancers that we know how to detect early (via PSA testing) and prevent (with drugs like finasteride). Yet it is far from clear that doing so does more good than harm: PSA testing has led to massive over diagnosis and overtreatment, and prevention has not become widespread due to concerns that finasteride lowers the risk of indolent, but not aggressive, disease.
The panel will focus on how to ensure that we practice medicine in such a way to maximize benefits and minimize harms of prostate cancer screening and prevention.
Peter C. Albertsen, MD, J. Jacques Carter, MD, Marc B. Garnick, MD, Andrew Vickers, Ph.D., moderator

9:45 Panel on Active Surveillance and Early Stage Disease
Active surveillance has become widely utilized for low-risk prostate cancer and has evolved significantly over the last two decades. However, many important questions and controversies remain. Can we define the molecular events that signal "progression" of low-grade disease? How to optimally identify the "wolves in sheep's clothing," that is, those men who benefit from early treatment? How best to integrate MRI and biomarkers into treatment decision making? Which intermediate risk patients are candidates for surveillance? What interventions (diet, exercise, micronutrients, pharmacologic agents) are warranted to reduce the risk of biological progression? What is the most efficient and cost-effective way to follow patients longitudinally? Is serial biopsy still required, and if so? Clair J. Beard, MD, Adam S. Kibel, MD, Eric A. Klein, MD, Laurence Klotz, MD, laurence Klotz, MD, moderator; Clare M. Tempany, MD

11:00 Break

11:15 Presentation of Austin and Colbert Awards
Charles Austin Award presented to Fran and Stan Klein.
Jack Colbert Memorial Award presented to Marc Garnick, MD.

11:30 Panel on Metastatic Disease and Research
Metastatic prostate cancer is the second-leading cause of cancer-related death among men in the United States, responsible for more than 25,000 deaths per year. While the disease remains inscrutable, meaningful strides have been made recently in its treatment and in understanding of prostate cancer biology. One important revelation is the importance of androgen signaling even after the disease proves refractory to first-line hormonal therapy. This has led to development of effective new agents that form the backbone of modern treatment.
Further discoveries in the areas of radiopharmaceuticals, immunotherapy and targeted therapy based on tumor genetics are broadening the prostate cancer armamentarium. The panel will focus on the latest developments in management of advanced prostate cancer.
William G. Nelson, MD, Susan F. Sloviter, MD, Mary Ellen Taplin, MD, moderator

1:00PM Closing

20th Anniversary Massachusetts Prostate Cancer Symposium

PLEASE REGISTER BY MAY 1, 2017
MAIL year, completed registration form to: MPPC, c/o Ann Boughie, 200 Lincoln St., #201, Boston, MA 02111
FAX 617.482.3049 ONLNE AT: www.mappc.org

REGISTRATION INFORMATION
Name
Address
City State Zip
Phone
Email

Yes, I/we want to attend the 20th Anniversary Massachusetts Prostate Cancer Symposium on Friday, May 12, 2017 at the Boston Marriott Copley Place. There is no fee for the Symposium or breakfast, but attendees are invited to make voluntary contributions of $10 to partially underwrite the symposium costs.

CONTRIBUTIONS
$25 for breakfast (optional)
$150 (includes one-year membership in MPPC)
$5 Other amount
TOTAL

ENCLOSED IS MY CHECK: (Checks should be made payable to MPPC and mailed to the address above.)

PLEASE CHARGE MY: ( ) MC ( ) VISA ( ) AMERICAN EXPRESS

Ticket
Day Date

Print Name and Card

Signature

Gifts to the Massachusetts Prostate Cancer Coalition, a 501(c)(3) public charity, may be tax deductible to the extent allowed by law. MPPC Tax ID: 04-3493881

Panelists subject to change.

The Massachusetts Prostate Cancer Coalition (MPPC) educates, connects, and supports one-at-a-time, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.

The Symposium has been held annually since 1997. More than 3000 people have attended the annual symposium.
2007 KEYNOTE
Laurence Klotz, MD is past chief of urology at Sunnybrook Health Sciences Centre and a professor of surgery at the University of Toronto. He is chairman of the World Urological Oncology Federation and the associate editor of the Journal of Urology, responsible for prostate cancer.

2006 KEYNOTE
William G. Nelson, MD, Ph.D. is the Marion I. Knott Director and professor of oncology and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is the co-discoverer of the most common genome alteration in prostate cancer.

2008 KEYNOTE
Susan F. Siovin, MD, Ph.D. is a medical oncologist at Memorial Sloan Kettering Cancer Center, specializing in bladder and prostate cancer. Mary-Ellen Taplin, MD is chair of the Executive Committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and an associate professor of medicine at Harvard Medical School. Claire M. Tempany, MD is professor of radiology at Harvard Medical School and Ferenc Jolesz Chair of Research, Radiology at Brigham and Women’s Hospital. Her major areas of research interest are MR imaging of the pelvis (specifically prostate cancer) and image-guided therapy.

2016 KEYNOTE
Andrew Vickers, Ph.D. is attending research methodologist at Memorial Sloan Kettering Cancer Center. His research falls into three broad areas: randomized trials, surgical outcomes research, and molecular marker studies. A particular focus of his work is in the detection and initial treatment of prostate cancer.

20th Anniversary Massachusetts Prostate Cancer Symposium
PLEASE REGISTER BY MAY 1, 2017
MAIL your completed registration form to: MPCC, c/o Green Associates, 200 Lincoln St., #201, Boston, MA 02111 FAX: 617.482.3049 ONLINE AT www.masspcc.org
For more information, call 617.482.3044 x28 or email info@masspcc.org

REGISTRATION INFORMATION
Name
Organization, if applicable
Address
City/State/Zip
Phone
Email
Spouse/Companion (Name, if attending)
Email
D Yes, I/we want to attend the 20th Anniversary Massachusetts Prostate Cancer Symposium on Friday, May 12, 2017 at the Boston Marriott Copley Place. There is no fee for the Symposium or breakfast, but attendees are invited to make voluntary contributions of $25 to partially underwrite the symposium costs.

CONTRIBUTIONS
D $25 for breakfast (optional)
D $60 (includes one-year membership in MPCC)
D $ Other amount
TOTAL $
D YES, I HAVE COMPLETED THE ATTACHED REGISTRATION FORM.

The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men at risk of, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.

The Symposium has been held annually since 1997. More than 700 people have attended the annual symposium.

Symposium Schedule
7:30AM Registration and Breakfast
8:00 Panel on Prevention and Screening
Prostate cancer is one of the few cancers that we know how to detect early (via PSA testing) and prevent (with drugs like flutamide). Yet it is far from clear that doing so does more good than harm: PSA testing has led to overdiagnosis and overtreatment, and prevention has not become widespread due to concerns that financing lowers the risk of overtreatment, but not aggressive disease. The panel will focus on how to ensure that we practice medicine in such a way to maximize benefits and minimize harms of prostate cancer screening and prevention.

Peter C. Albertsen, MD, J. Jacques Carter, MD, Marc B. Garnick, MD, Andrew Vickers, Ph.D., moderator

9:45 Panel on Active Surveillance and Early Stage Disease
Active surveillance has become widely utilized for low-risk prostate cancer and has evolved significantly over the last two decades. However, many important questions and controversies remain. Can we define the molecular events that signal “progression” of low-grade disease? How do optimally identify the “wolves in sheep’s clothing”? i.e., those who benefit from early treatment? How best to integrate MRI and biomarkers into treatment decision making? Which intermediate risk patients are candidates for surveillance? What interventions (diet, exercise, microinjections, pharmacologic agents) are warranted to reduce the risk of biological progression? What is the most efficient and cost-effective way to follow patients longitudinally? Is serial biopsy still required, and when?

Claire J. Beard, MD, Adam S. Kibel, MD, Eric A. Klein, MD, Laurence Klotz, MD, moderator; Claire M. Tempany, MD

11:00 Break

11:15 Presentation of Austin and Coldert Awards
Charles Austin Award presented to Fran and Stan Klein. Jack Colbert Memorial Award presented to Marc Garnick, MD.

11:30 Panel on Metastatic Disease and Research
Metastatic prostate cancer is the second-leading cause of cancer-related death among men in the United States, responsible for more than 25,000 deaths per year. While the disease remains incurable, meaningful strides have been made recently in its treatment and in understanding of prostate cancer biology. One important revelation is the importance of androgen signaling even after the disease proves refractory to first-line hormonal therapy. This has led to development of effective new agents that form the backbone of modern treatment. Further discoveries in the areas of radiopharmaceuticals, immunotherapy and targeted therapy based on tumor genetics are broadening the prostate cancer armamentarium. The panel will focus on the latest developments in management of advanced prostate cancer.

William G. Nelson, MD, Susan F. Slavin, MD, Mary-Elle Taplin, MD, moderator

1:00PM Closing
Leading prostate cancer specialists provide up-to-date information on the latest in prostate cancer diagnosis, treatment and research — in user-friendly language!

Plan to attend!

20TH ANNIVERSARY
MASSACHUSETTS PROSTATE CANCER SYMPOSIUM
Friday, May 12, 2017
7:30 AM – 1:00 PM
Boston Marriott Copley Place
Boston, Massachusetts